Damian Wild

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. ncbi request reprint DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals
    Damian Wild
    Division of Radiological Chemistry, Institute of Nuclear Medicine, Department of Radiology, University Hospital Basel, Basel, Switzerland
    Eur J Nucl Med Mol Imaging 30:1338-47. 2003
  2. ncbi request reprint 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5
    Damian Wild
    Clinic and Institute of Nuclear Medicine, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland
    Eur J Nucl Med Mol Imaging 32:724. 2005
  3. ncbi request reprint [Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting
    Damian Wild
    Clinic and Institute of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
    J Nucl Med 47:2025-33. 2006
  4. doi request reprint Glucagon-like peptide 1-receptor scans to localize occult insulinomas
    Damian Wild
    N Engl J Med 359:766-8. 2008
  5. doi request reprint Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors
    Damian Wild
    Institute of Nuclear Medicine, University College Hospital, London, United Kingdom
    J Nucl Med 54:364-72. 2013
  6. doi request reprint New pansomatostatin ligands and their chelated versions: affinity profile, agonist activity, internalization, and tumor targeting
    Mihaela Ginj
    Division of Radiological Chemistry, University Hospital Basel, Basel, Switzerland
    Clin Cancer Res 14:2019-27. 2008
  7. doi request reprint Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT
    Damian Wild
    Clinic and Institute of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
    J Nucl Med 51:1059-67. 2010
  8. ncbi request reprint [Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma
    Andreas Wicki
    Institute of Biochemistry and Genetics, DKBW, Medical School, University of Basel, Basel, Switzerland
    Clin Cancer Res 13:3696-705. 2007
  9. doi request reprint Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN)
    Damian Wild
    Division of Radiological Chemistry, University Hospital, Basel, Switzerland
    Cancer Res 71:1009-18. 2011
  10. pmc Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors
    Mihaela Ginj
    Division of Radiological Chemistry, Institute of Nuclear Medicine, Department of Radiology, University Hospital Basel, Petersgraben 4, CH 4031 Basel, Switzerland
    Proc Natl Acad Sci U S A 103:16436-41. 2006

Collaborators

Detail Information

Publications16

  1. ncbi request reprint DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals
    Damian Wild
    Division of Radiological Chemistry, Institute of Nuclear Medicine, Department of Radiology, University Hospital Basel, Basel, Switzerland
    Eur J Nucl Med Mol Imaging 30:1338-47. 2003
    ..These very promising preclinical data justify the use of this new radiopeptide for imaging and potentially internal radiotherapy studies in patients...
  2. ncbi request reprint 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5
    Damian Wild
    Clinic and Institute of Nuclear Medicine, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland
    Eur J Nucl Med Mol Imaging 32:724. 2005
  3. ncbi request reprint [Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting
    Damian Wild
    Clinic and Institute of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
    J Nucl Med 47:2025-33. 2006
    ..The goal of this study was to establish a tumor model for GLP-1 receptor targeting and to use a newly designed exendin-4-DTPA (DTPA is diethylenetriaminepentaacetic acid) conjugate for GLP-1 receptor targeting...
  4. doi request reprint Glucagon-like peptide 1-receptor scans to localize occult insulinomas
    Damian Wild
    N Engl J Med 359:766-8. 2008
  5. doi request reprint Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors
    Damian Wild
    Institute of Nuclear Medicine, University College Hospital, London, United Kingdom
    J Nucl Med 54:364-72. 2013
    ..The goal of this study was to prospectively compare (68)Ga-DOTANOC and (68)Ga-DOTATATE PET/CT in the same patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and to evaluate the clinical impact of (68)Ga-DOTANOC PET/CT...
  6. doi request reprint New pansomatostatin ligands and their chelated versions: affinity profile, agonist activity, internalization, and tumor targeting
    Mihaela Ginj
    Division of Radiological Chemistry, University Hospital Basel, Basel, Switzerland
    Clin Cancer Res 14:2019-27. 2008
    ..Currently used targeting peptides mainly have sst2 affinity. We aimed at developing (radio)peptides that bind with high affinity to all receptor subtypes...
  7. doi request reprint Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT
    Damian Wild
    Clinic and Institute of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
    J Nucl Med 51:1059-67. 2010
    ..The aim of this study was the preclinical evaluation of [Lys(40)(Ahx-DOTA-(68)Ga)NH(2)]-exendin-4 for PET/CT and [Lys(40)(Ahx-hydrazinonicotinamide [HYNIC]-(99m)Tc)NH(2)]-exendin-4 for SPECT/CT...
  8. ncbi request reprint [Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma
    Andreas Wicki
    Institute of Biochemistry and Genetics, DKBW, Medical School, University of Basel, Basel, Switzerland
    Clin Cancer Res 13:3696-705. 2007
    ..In this study, we investigated the therapeutic potential of [Lys(40)(Ahx-DTPA-(111)In)NH(2)]-Exendin-4, an (111)In-labeled agonist of GLP-1, in a transgenic mouse model of human insulinoma...
  9. doi request reprint Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN)
    Damian Wild
    Division of Radiological Chemistry, University Hospital, Basel, Switzerland
    Cancer Res 71:1009-18. 2011
    ..Furthermore, (213)Bi-DOTA-PESIN has a better safety profile than (213)Bi-AMBA, and represents a possible new approach for use in peptide-receptor radionuclide α-therapy treating recurrent prostate cancer...
  10. pmc Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors
    Mihaela Ginj
    Division of Radiological Chemistry, Institute of Nuclear Medicine, Department of Radiology, University Hospital Basel, Petersgraben 4, CH 4031 Basel, Switzerland
    Proc Natl Acad Sci U S A 103:16436-41. 2006
    ..Antagonist radioligands for other peptide receptors need to be evaluated in nuclear oncology as a result of this paradigm shift...
  11. ncbi request reprint DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours
    Hanwen Zhang
    Division of Radiological Chemistry, Department of Radiology, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland
    Eur J Nucl Med Mol Imaging 34:1198-208. 2007
    ....
  12. doi request reprint Distribution pattern of 68Ga-DOTATATE in disease-free patients
    Manu Shastry
    Institute of Nuclear Medicine, University College Hospital
    Nucl Med Commun 31:1025-32. 2010
    ....
  13. ncbi request reprint Coregistered iodine-131 single photon emission computed tomography/computed tomography reveals dedifferentiation in a metastatic follicular thyroid carcinoma
    Martin A Walter
    Division of Endocrinology, Diabetes and Clinical Nutrition, University Hospital Basel, Basel, Switzerland
    Thyroid 16:1063-4. 2006
  14. doi request reprint Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas
    Damian Wild
    Institute of Nuclear Medicine, University College Hospital, London, United Kingdom
    J Nucl Med 52:1073-8. 2011
    ..Here, the role of GLP-1 and sst(2) receptor imaging in the management of malignant insulinoma patients was investigated...
  15. ncbi request reprint In-line (18)F-fluorodeoxyglucose positron emission tomography with computed tomography (PET/CT) in patients with carcinoma of the sinus/nasal area and orbit
    Damian Wild
    Division of Nuclear Medicine, Institute of Diagnostic Radiology, University Hospital Zurich, Raemistr 100, CH 8091 Zurich, Switzerland
    J Craniomaxillofac Surg 34:9-16. 2006
    ..The use of positron emission tomography (PET) with (18)F-fluorodeoxyglucose (FDG) in such patients is as yet less well established...
  16. ncbi request reprint Uptake of 18F-fluorocholine, 18F-fluoroethyl-L-tyrosine, and 18F-FDG in acute cerebral radiation injury in the rat: implications for separation of radiation necrosis from tumor recurrence
    Nicolas Spaeth
    PET Center, Division of Nuclear Medicine, University Hospital Zurich, Zurich, Switzerland
    J Nucl Med 45:1931-8. 2004
    ..This study assessed uptake of these tracers in experimental radiation injury...